Project: Restoring endocannabinoid homeostasis to create the first effective & safe pharmacotherapy for PTSD
| Acronym | EndoCARE (Reference Number: 114985) |
| Duration | 03/02/2021 - 03/08/2023 |
| Project Topic | EndoCARE aims to develop the first safe and effective pharmacotherapy for Post-Traumatic Stress Disorder (PTSD) based on our unique Selective Endocannabinoid Reuptake Inhibitor (SERI) SYT-510. With a novel mode of action (MoA), SYT-510 restores physiological endocannabinoid (ECx) levels. Here, we combine MoA research with efficacy studies in novel PTSD animal model and preclinical neuroimaging and biomarker discovery, enabling a translational preclinical package to derisk our clinical programme. |
| Network | Eurostars 2 |
| Call | Eurostars Cut–off 14 |